200 related articles for article (PubMed ID: 22828183)
1. The use of biologic agents in pediatric inflammatory bowel disease.
Yang LS; Alex G; Catto-Smith AG
Curr Opin Pediatr; 2012 Oct; 24(5):609-14. PubMed ID: 22828183
[TBL] [Abstract][Full Text] [Related]
2. [Biological treatment of inflammatory bowel diseases in children in the years 2004-2013 in Poland].
Iwańczak B; Ryzko J; Kierkuś J; Jankowski P; Sładek M; Wasilewska A; Landowski P; Szczepanik M; Krzesiek E; Sienkiewicz E; Szaflarska-Popławska A; Wiecek S; Kwiecien J; Kacperska M; Korczowski B; Maślana J
Pol Merkur Lekarski; 2014 May; 36(215):311-5. PubMed ID: 24964507
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients.
Mohabbat AB; Sandborn WJ; Loftus EV; Wiesner RH; Bruining DH
Aliment Pharmacol Ther; 2012 Sep; 36(6):569-74. PubMed ID: 22779779
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
Trinder MW; Lawrance IC
J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
[TBL] [Abstract][Full Text] [Related]
5. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
Rutgeerts P; Van Assche G; Vermeire S
Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
[TBL] [Abstract][Full Text] [Related]
6. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
Hanauer SB
Gut; 2007 Sep; 56(9):1181-3. PubMed ID: 17698862
[TBL] [Abstract][Full Text] [Related]
7. [Biologicals in gastroenterology: TNF-blockers].
Scharl M; Rogler G
Dtsch Med Wochenschr; 2010 Nov; 135(45):2243-52. PubMed ID: 21046532
[TBL] [Abstract][Full Text] [Related]
8. [Biological therapy as treatment of inflammatory bowel diseases].
Agnholt J
Ugeskr Laeger; 2008 Jun; 170(24):2152-6. PubMed ID: 18565302
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
[TBL] [Abstract][Full Text] [Related]
11. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
12. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease.
Orlando A; Armuzzi A; Papi C; Annese V; Ardizzone S; Biancone L; Bortoli A; Castiglione F; D'Incà R; Gionchetti P; Kohn A; Poggioli G; Rizzello F; Vecchi M; Cottone M; ;
Dig Liver Dis; 2011 Jan; 43(1):1-20. PubMed ID: 20843756
[TBL] [Abstract][Full Text] [Related]
13. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
Lam MC; Bressler B
Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
[TBL] [Abstract][Full Text] [Related]
14. [Inflammatory diseases of the intestines].
Felley C; Guyot J; Hess J; Mottet C; Delarive J; Michetti P
Rev Med Suisse; 2006 Jan; 2(49):191-4, 196-8, 201-3. PubMed ID: 16493962
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppression in inflammatory bowel disease: traditional, biological or both?
Van Assche G; Vermeire S; Rutgeerts P
Curr Opin Gastroenterol; 2009 Jul; 25(4):323-8. PubMed ID: 19417645
[TBL] [Abstract][Full Text] [Related]
16. Antitumor necrosis factor treatment for pediatric inflammatory bowel disease.
de Bie CI; Escher JC; de Ridder L
Inflamm Bowel Dis; 2012 May; 18(5):985-1002. PubMed ID: 21936033
[TBL] [Abstract][Full Text] [Related]
17. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.
Lawrance IC; Radford-Smith GL; Bampton PA; Andrews JM; Tan PK; Croft A; Gearry RB; Florin TH
J Gastroenterol Hepatol; 2010 Nov; 25(11):1732-8. PubMed ID: 21039834
[TBL] [Abstract][Full Text] [Related]
18. Emerging biologic therapies in inflammatory bowel disease.
Lim WC; Hanauer SB
Rev Gastroenterol Disord; 2004; 4(2):66-85. PubMed ID: 15184826
[TBL] [Abstract][Full Text] [Related]
19. Controversies with aminosalicylates in inflammatory bowel disease.
Lim WC; Hanauer SB
Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
[TBL] [Abstract][Full Text] [Related]
20. Advances in medical therapy of inflammatory bowel disease.
Panaccione R; Ferraz JG; Beck P
Curr Opin Pharmacol; 2005 Dec; 5(6):566-72. PubMed ID: 16213789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
